INTERVIEW: Biogen's Danos on why now is gene therapy's time
This article was originally published in Scrip
Executive Summary
After a few decades of searching for viable means for delivering gene therapy, Biogen Idec's Olivier Danos said the field finally is at a point where experimental treatments can be delivered on a commercial scale.
You may also be interested in...
Bioverativ Fills Gap In Pipeline With $400m True North Buy
Bioverativ revealed its first transaction since spinning out from Biogen with the acquisition of True North for $400m plus up to $425m in milestone payments. The deal gives Bioverativ a clinical asset, helping to fill the gap between preclinical programs and commercial products in its R&D pipeline.
Biogen Shores Up Gene Therapy Ambitions With New Deal
Biogen Inc. has furthered its gene therapy ambitions by entering into a broad alliance with the University of Pennsylvania that could see it paying out up to $2bn in research funding and other payments. Biogen has made a series of moves over the past couple of years to build up its gene therapy research.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.